Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

|Videos|April 1, 2022

Clinical Experiences of Using Circulating Tumor DNA

Author(s)Mary Scoviak, Managing Editor

In this third part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, highlights the in practice experiences in using circulating tumor DNA for merkel cell carcinoma (MCC).

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

New Frontiers in CSCC: Experts Weigh Immunotherapy Options and Collaborative Referral Pathways

ByMarie Bosslett, Assistant Editor

July 17th 2026

Medicus Pharma Targets Gorlin Syndrome and BCC Backlog with Novel Immuno-Oncology Patch

ByRaza Bokhari, MD,Marie Bosslett, Assistant Editor

June 17th 2026

Raza Bokhari, MD: How SkinJect is Changing Nonmelanoma Skin Cancer Care

ByRaza Bokhari, MD,Marie Bosslett, Assistant Editor

June 16th 2026

The Expanding Role of Immunotherapies for Non-Melanoma Skin Cancers

ByJoshua Burshtein, MD,Todd Schlesinger, MD, FAAD, FASMS

June 15th 2026

Tips for Managing Pain and Local Skin Reactions During Photodynamic Therapy

ByNeal Bhatia, MD,Kaitlyn Bader, Assistant Managing Editor

May 27th 2026

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

New Review Confirms How Nonmedicated Skin Care Vehicles Drive Clinical Improvement

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

Dermatology Times Spot Test: July 19, 2026

Social Media Mythbusters: The Summer Skin Care "Shutdown"

New Frontiers in CSCC: Experts Weigh Immunotherapy Options and Collaborative Referral Pathways